Form 4: Agios Pharmaceuticals Director Jeffrey Capello Reports Significant Equity Grants and RSU Vesting

Agios Pharmaceuticals, Inc. Director Jeffrey D. Capello reported the acquisition of 2,120 common shares from RSU vesting and new grants of 2,861 restricted stock units and 15,768 stock options.

Summary

• Jeffrey D. Capello, a Director at Agios Pharmaceuticals, Inc. (AGIO), reported several equity transactions.
• On June 20, 2025, Mr. Capello acquired 2,120 shares of common stock through the vesting of previously granted restricted stock units (RSUs). These RSUs were originally granted on June 20, 2024, and vested in full on June 20, 2025.
• On June 18, 2025, Mr. Capello was granted 2,861 new restricted stock units. These RSUs are scheduled to vest in full on June 18, 2026.
• Also on June 18, 2025, Mr. Capello received a grant of 15,768 stock options with an exercise price of $35.5 per share. These options will vest 100% on June 18, 2026, and have an expiration date of June 18, 2035.
• Following these transactions, Mr. Capello's direct beneficial ownership of common stock stands at 6,073 shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates continued insider ownership and alignment through equity grants, without any reported sales. This is a routine compensation event, but the grants themselves are a positive signal of commitment.

Positives

• The Director received significant new equity grants (2,861 RSUs and 15,768 stock options), indicating continued alignment of interests with shareholders.
• The vesting of 2,120 restricted stock units into common stock demonstrates the realization of previously awarded equity compensation.

Future Outlook

The document indicates future vesting events for the newly granted equity, with 2,861 restricted stock units and 15,768 stock options scheduled to vest in full on June 18, 2026. Vested shares from RSUs will be delivered within three business days after vesting.

Management Comments

• While no direct quotes were provided, the grants reflect the company's ongoing equity compensation strategy for its directors, aligning their interests with long-term shareholder value.

Industry Context

This Form 4 filing is a routine disclosure of insider equity transactions, common across publicly traded companies. The granting of restricted stock units and stock options is a standard practice in the biotechnology and pharmaceutical industry to incentivize and retain key personnel, including directors, by linking their compensation to the company's stock performance and long-term success. The exercise price of $35.5 for the options provides a benchmark for future stock performance expectations from the grant date.

Stakeholder Impact

• Shareholders: The grants align the director's interests with shareholders, potentially signaling confidence in future company performance. The increase in direct common stock ownership also increases the director's stake.
• Employees: While not directly impacting employees, the equity compensation structure for directors often mirrors or influences broader employee incentive programs.

Next Steps

• Delivery of 2,120 common shares to the reporting person within three business days after June 20, 2025.
• Vesting of 2,861 restricted stock units on June 18, 2026.
• Vesting of 15,768 stock options on June 18, 2026.
• Potential exercise of 15,768 stock options by June 18, 2035.

Key Dates

Keywords

Agios Pharmaceuticals, AGIO, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Equity Compensation, Director, Jeffrey Capello, Stock Grant, Vesting